Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 20, 2026, 5:00 pm
Author: Getaka|Social: XLinkedIn

Syngene International Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 20, 2026, 5:00 pm

Market Cap 17,880 Cr.
Current Price 444
Intrinsic Value₹443.68
High / Low 761/426
Stock P/E43.7
Book Value 118
Dividend Yield0.28 %
ROCE13.5 %
ROE10.5 %
Face Value 10.0
PEG Ratio13.18

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Syngene International Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Mipco Seamless Rings (Gujarat) Ltd 9.18 Cr. 25.6 37.4/22.0918 3.710.00 %%% 10.0
MPIL Corporation Ltd 19.5 Cr. 342 787/330 2420.13 %12.8 %15.5 % 10.0
FGP Ltd 11.8 Cr. 9.89 13.7/7.3256.0 3.090.00 %0.00 %0.89 % 10.0
Logica Infoway Ltd 384 Cr. 216 267/17328.1 53.00.00 %14.3 %14.1 % 10.0
CRP Risk Management Ltd 10.8 Cr. 6.18 8.32/5.61 34.60.00 %0.00 %0.00 % 10.0
Industry Average6,281.50 Cr237.50261.45103.340.05%48.42%7.44%9.00

All Competitor Stocks of Syngene International Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 7869948089108549177908919441,018874911917
Expenses 555680596656622600620646660674668711708
Operating Profit 231314212254232317170245284344206200209
OPM % 29%32%26%28%27%35%22%27%30%34%24%22%23%
Other Income 172324142616501618191815-55
Interest 14101013111312131216121312
Depreciation 9596102105108111107111109106111116114
Profit before tax 1402311231511382091011371812401018528
Tax % 22%23%24%23%19%10%25%23%27%24%14%21%47%
Net Profit 1101799311611218976106131183876715
EPS in Rs 2.734.452.322.902.774.691.882.643.264.552.151.670.37

Last Updated: February 3, 2026, 11:46 pm

Below is a detailed analysis of the quarterly data for Syngene International Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 917.00 Cr.. The value appears strong and on an upward trend. It has increased from 911.00 Cr. (Sep 2025) to 917.00 Cr., marking an increase of 6.00 Cr..
  • For Expenses, as of Dec 2025, the value is 708.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 711.00 Cr. (Sep 2025) to 708.00 Cr., marking a decrease of 3.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 200.00 Cr. (Sep 2025) to 209.00 Cr., marking an increase of 9.00 Cr..
  • For OPM %, as of Dec 2025, the value is 23.00%. The value appears strong and on an upward trend. It has increased from 22.00% (Sep 2025) to 23.00%, marking an increase of 1.00%.
  • For Other Income, as of Dec 2025, the value is -55.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Sep 2025) to -55.00 Cr., marking a decrease of 70.00 Cr..
  • For Interest, as of Dec 2025, the value is 12.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 13.00 Cr. (Sep 2025) to 12.00 Cr., marking a decrease of 1.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 114.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 116.00 Cr. (Sep 2025) to 114.00 Cr., marking a decrease of 2.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 85.00 Cr. (Sep 2025) to 28.00 Cr., marking a decrease of 57.00 Cr..
  • For Tax %, as of Dec 2025, the value is 47.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Sep 2025) to 47.00%, marking an increase of 26.00%.
  • For Net Profit, as of Dec 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 67.00 Cr. (Sep 2025) to 15.00 Cr., marking a decrease of 52.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 0.37. The value appears to be declining and may need further review. It has decreased from 1.67 (Sep 2025) to 0.37, marking a decrease of 1.30.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 4:33 am

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,4231,8262,0122,1842,6043,1933,4893,6423,747
Expenses 9491,2891,3941,5071,8062,2512,4722,5982,714
Operating Profit 4745376186787989421,0171,0451,033
OPM % 33%29%31%31%31%30%29%29%28%
Other Income 53751539420637710170
Interest 233235282445475353
Depreciation 131164219274310366426433442
Profit before tax 372415517469484594621660608
Tax % 18%20%20%14%18%22%18%25%
Net Profit 305332412405396464510496468
EPS in Rs 7.648.2910.3010.129.8811.5712.6912.3311.63
Dividend Payout % 7%3%0%0%10%11%10%10%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)8.85%24.10%-1.70%-2.22%17.17%9.91%-2.75%
Change in YoY Net Profit Growth (%)0.00%15.24%-25.80%-0.52%19.39%-7.26%-12.66%

Syngene International Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:13%
3 Years:12%
TTM:7%
Compounded Profit Growth
10 Years:%
5 Years:6%
3 Years:4%
TTM:6%
Stock Price CAGR
10 Years:15%
5 Years:7%
3 Years:5%
1 Year:-28%
Return on Equity
10 Years:%
5 Years:13%
3 Years:12%
Last Year:11%

Last Updated: September 5, 2025, 1:41 pm

Balance Sheet

Last Updated: December 4, 2025, 2:04 am

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 200200400400401401402402403
Reserves 1,5201,7681,7762,4212,8973,2173,8564,3244,332
Borrowings 7878137738931,022815555578582
Other Liabilities 6819221,2141,1691,2451,3981,3391,4911,226
Total Liabilities 3,1893,7044,1634,8835,5645,8316,1526,7966,542
Fixed Assets 1,0301,3772,0202,2012,3932,6672,8502,8023,049
CWIP 1552742342373461778381,266989
Investments 1587167767021,034918548647547
Other Assets 1,8461,3371,1331,7431,7902,0691,9162,0811,957
Total Assets 3,1893,7044,1634,8835,5645,8316,1526,7966,542

Below is a detailed analysis of the balance sheet data for Syngene International Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 403.00 Cr.. The value appears strong and on an upward trend. It has increased from 402.00 Cr. (Mar 2025) to 403.00 Cr., marking an increase of 1.00 Cr..
  • For Reserves, as of Sep 2025, the value is 4,332.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,324.00 Cr. (Mar 2025) to 4,332.00 Cr., marking an increase of 8.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 582.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 578.00 Cr. (Mar 2025) to 582.00 Cr., marking an increase of 4.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 1,226.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,491.00 Cr. (Mar 2025) to 1,226.00 Cr., marking a decrease of 265.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 6,542.00 Cr.. The value appears to be improving (decreasing). It has decreased from 6,796.00 Cr. (Mar 2025) to 6,542.00 Cr., marking a decrease of 254.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 3,049.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,802.00 Cr. (Mar 2025) to 3,049.00 Cr., marking an increase of 247.00 Cr..
  • For CWIP, as of Sep 2025, the value is 989.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,266.00 Cr. (Mar 2025) to 989.00 Cr., marking a decrease of 277.00 Cr..
  • For Investments, as of Sep 2025, the value is 547.00 Cr.. The value appears to be declining and may need further review. It has decreased from 647.00 Cr. (Mar 2025) to 547.00 Cr., marking a decrease of 100.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 1,957.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,081.00 Cr. (Mar 2025) to 1,957.00 Cr., marking a decrease of 124.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 6,542.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,796.00 Cr. (Mar 2025) to 6,542.00 Cr., marking a decrease of 254.00 Cr..

Notably, the Reserves (4,332.00 Cr.) exceed the Borrowings (582.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 4466306777015818241,0421,168
Cash from Investing Activity + -349-646-424-629-611-653-494-744
Cash from Financing Activity + -79-72-22658-31-342-551-142
Net Cash Flow 18-8828130-62-172-4281

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-313.00-276.00-155.00-215.00797.00127.00-554.00-577.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 6868727971614653
Inventory Days 82301841871419460
Days Payable 195154156167113109100136
Cash Conversion Cycle -44-56-66-47459240-23
Working Capital Days -48-103-172-66-43-14-27-51
ROCE %17%17%14%13%15%15%14%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters 64.86%54.88%54.80%54.79%54.79%54.79%54.72%54.72%52.74%52.74%52.68%52.68%
FIIs 16.87%23.31%23.19%23.55%21.20%20.92%20.64%20.72%20.65%19.47%16.51%16.31%
DIIs 7.03%10.71%11.20%11.70%14.63%15.80%16.78%17.49%19.52%21.50%24.05%24.62%
Public 10.77%10.65%10.23%9.47%9.07%8.18%7.44%6.74%6.79%5.99%6.45%6.08%
Others 0.47%0.46%0.60%0.48%0.32%0.31%0.43%0.34%0.29%0.29%0.31%0.30%
No. of Shareholders 1,27,9641,24,0141,25,4551,25,9921,21,8801,15,8501,20,0181,07,3381,28,8061,25,0901,42,3101,36,061

Shareholding Pattern Chart

No. of Shareholders

Syngene International Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Mirae Asset Large & Midcap Fund 5,189,854 0.77 337.864,555,2772026-01-25 06:22:2913.93%
Nippon India Small Cap Fund 4,906,326 0.47 319.44,592,9702026-01-25 02:17:236.82%
Mirae Asset Focused Fund 4,207,261 3.52 273.894,326,5122026-01-26 00:59:00-2.76%
Nippon India Focused Fund 4,008,177 2.97 260.933,708,1772025-12-14 09:10:178.09%
Mirae Asset ELSS Tax Saver Fund 3,855,733 0.92 251.013,387,6812025-12-15 00:57:4813.82%
ICICI Prudential ELSS Tax Saver Fund 3,770,138 1.66 245.443,400,2672025-12-08 06:31:0410.88%
DSP ELSS Tax Saver Fund 3,737,983 1.38 243.34N/AN/AN/A
Mirae Asset Midcap Fund 3,571,092 1.26 232.483,471,9922026-01-25 01:13:532.85%
DSP Large & Mid Cap Fund 3,369,970 1.25 219.39N/AN/AN/A
ICICI Prudential Multicap Fund 3,273,806 1.31 213.121,811,6852025-12-08 06:31:0480.71%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 12.3512.7111.599.9410.18
Diluted EPS (Rs.) 12.3412.6911.519.8210.11
Cash EPS (Rs.) 23.0723.2820.7017.6016.98
Book Value[Excl.RevalReserv]/Share (Rs.) 117.44105.9290.1382.2870.53
Book Value[Incl.RevalReserv]/Share (Rs.) 117.44105.9290.1382.2870.53
Revenue From Operations / Share (Rs.) 90.4986.7879.5464.9754.61
PBDIT / Share (Rs.) 27.6727.4925.0421.1818.41
PBIT / Share (Rs.) 16.9216.8915.9113.4511.55
PBT / Share (Rs.) 16.4015.4414.7912.0911.73
Net Profit / Share (Rs.) 12.3312.6911.579.8810.12
NP After MI And SOA / Share (Rs.) 12.3312.6911.579.8810.12
PBDIT Margin (%) 30.5731.6731.4832.5933.71
PBIT Margin (%) 18.6919.4620.0020.7021.14
PBT Margin (%) 18.1117.7918.5918.6021.48
Net Profit Margin (%) 13.6214.6114.5415.1918.53
NP After MI And SOA Margin (%) 13.6214.6114.5415.1918.53
Return on Networth / Equity (%) 10.4911.9712.8312.0014.35
Return on Capital Employeed (%) 12.6113.5613.7512.4312.31
Return On Assets (%) 7.308.297.967.118.29
Long Term Debt / Equity (X) 0.000.020.130.160.18
Total Debt / Equity (X) 0.020.030.150.230.27
Asset Turnover Ratio (%) 0.560.580.550.490.48
Current Ratio (X) 1.641.712.041.791.59
Quick Ratio (X) 1.531.501.761.651.54
Inventory Turnover Ratio (X) 18.493.063.526.4513.01
Dividend Payout Ratio (NP) (%) 10.139.868.630.000.00
Dividend Payout Ratio (CP) (%) 5.415.374.820.000.00
Earning Retention Ratio (%) 89.8790.1491.370.000.00
Cash Earning Retention Ratio (%) 94.5994.6395.180.000.00
Interest Coverage Ratio (X) 20.9723.4122.2435.2226.58
Interest Coverage Ratio (Post Tax) (X) 9.7412.0411.2718.7014.35
Enterprise Value (Cr.) 28558.1327786.5423908.8424195.4521863.70
EV / Net Operating Revenue (X) 7.847.967.499.2910.01
EV / EBITDA (X) 25.6425.1523.7828.5029.69
MarketCap / Net Operating Revenue (X) 8.028.097.479.199.95
Retention Ratios (%) 89.8690.1391.360.000.00
Price / BV (X) 6.186.636.607.257.70
Price / Net Operating Revenue (X) 8.028.097.479.199.95
EarningsYield 0.010.010.010.010.01

After reviewing the key financial ratios for Syngene International Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 12.35. This value is within the healthy range. It has decreased from 12.71 (Mar 24) to 12.35, marking a decrease of 0.36.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 12.34. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.34, marking a decrease of 0.35.
  • For Cash EPS (Rs.), as of Mar 25, the value is 23.07. This value is within the healthy range. It has decreased from 23.28 (Mar 24) to 23.07, marking a decrease of 0.21.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 117.44. It has increased from 105.92 (Mar 24) to 117.44, marking an increase of 11.52.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 117.44. It has increased from 105.92 (Mar 24) to 117.44, marking an increase of 11.52.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 90.49. It has increased from 86.78 (Mar 24) to 90.49, marking an increase of 3.71.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 27.67. This value is within the healthy range. It has increased from 27.49 (Mar 24) to 27.67, marking an increase of 0.18.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 16.92. This value is within the healthy range. It has increased from 16.89 (Mar 24) to 16.92, marking an increase of 0.03.
  • For PBT / Share (Rs.), as of Mar 25, the value is 16.40. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.40, marking an increase of 0.96.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 12.33. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.33, marking a decrease of 0.36.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 12.33. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.33, marking a decrease of 0.36.
  • For PBDIT Margin (%), as of Mar 25, the value is 30.57. This value is within the healthy range. It has decreased from 31.67 (Mar 24) to 30.57, marking a decrease of 1.10.
  • For PBIT Margin (%), as of Mar 25, the value is 18.69. This value is within the healthy range. It has decreased from 19.46 (Mar 24) to 18.69, marking a decrease of 0.77.
  • For PBT Margin (%), as of Mar 25, the value is 18.11. This value is within the healthy range. It has increased from 17.79 (Mar 24) to 18.11, marking an increase of 0.32.
  • For Net Profit Margin (%), as of Mar 25, the value is 13.62. This value exceeds the healthy maximum of 10. It has decreased from 14.61 (Mar 24) to 13.62, marking a decrease of 0.99.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.62. This value is within the healthy range. It has decreased from 14.61 (Mar 24) to 13.62, marking a decrease of 0.99.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 10.49. This value is below the healthy minimum of 15. It has decreased from 11.97 (Mar 24) to 10.49, marking a decrease of 1.48.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 12.61. This value is within the healthy range. It has decreased from 13.56 (Mar 24) to 12.61, marking a decrease of 0.95.
  • For Return On Assets (%), as of Mar 25, the value is 7.30. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 7.30, marking a decrease of 0.99.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.58 (Mar 24) to 0.56, marking a decrease of 0.02.
  • For Current Ratio (X), as of Mar 25, the value is 1.64. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.64, marking a decrease of 0.07.
  • For Quick Ratio (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 1.50 (Mar 24) to 1.53, marking an increase of 0.03.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 18.49. This value exceeds the healthy maximum of 8. It has increased from 3.06 (Mar 24) to 18.49, marking an increase of 15.43.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 10.13. This value is below the healthy minimum of 20. It has increased from 9.86 (Mar 24) to 10.13, marking an increase of 0.27.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.41. This value is below the healthy minimum of 20. It has increased from 5.37 (Mar 24) to 5.41, marking an increase of 0.04.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 89.87. This value exceeds the healthy maximum of 70. It has decreased from 90.14 (Mar 24) to 89.87, marking a decrease of 0.27.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.59. This value exceeds the healthy maximum of 70. It has decreased from 94.63 (Mar 24) to 94.59, marking a decrease of 0.04.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 20.97. This value is within the healthy range. It has decreased from 23.41 (Mar 24) to 20.97, marking a decrease of 2.44.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.74. This value is within the healthy range. It has decreased from 12.04 (Mar 24) to 9.74, marking a decrease of 2.30.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 28,558.13. It has increased from 27,786.54 (Mar 24) to 28,558.13, marking an increase of 771.59.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.84. This value exceeds the healthy maximum of 3. It has decreased from 7.96 (Mar 24) to 7.84, marking a decrease of 0.12.
  • For EV / EBITDA (X), as of Mar 25, the value is 25.64. This value exceeds the healthy maximum of 15. It has increased from 25.15 (Mar 24) to 25.64, marking an increase of 0.49.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 3. It has decreased from 8.09 (Mar 24) to 8.02, marking a decrease of 0.07.
  • For Retention Ratios (%), as of Mar 25, the value is 89.86. This value exceeds the healthy maximum of 70. It has decreased from 90.13 (Mar 24) to 89.86, marking a decrease of 0.27.
  • For Price / BV (X), as of Mar 25, the value is 6.18. This value exceeds the healthy maximum of 3. It has decreased from 6.63 (Mar 24) to 6.18, marking a decrease of 0.45.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 3. It has decreased from 8.09 (Mar 24) to 8.02, marking a decrease of 0.07.
  • For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Syngene International Ltd as of February 20, 2026 is: ₹434.37

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 20, 2026, Syngene International Ltd is Overvalued by 2.17% compared to the current share price ₹444.00

Intrinsic Value of Syngene International Ltd as of February 20, 2026 is: ₹448.77

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 20, 2026, Syngene International Ltd is Undervalued by 1.07% compared to the current share price ₹444.00

Last 5 Year EPS CAGR: 3.32%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of -65.50, which is a positive sign.
  2. The stock has a low average Cash Conversion Cycle of -7.38, which is a positive sign.
  3. The company has higher reserves (2,901.22 cr) compared to borrowings (757.56 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (2.22 cr) and profit (526.67 cr) over the years.
  1. The stock has a low average ROCE of 13.13%, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Syngene International Ltd:
    1. Net Profit Margin: 13.62%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 12.61% (Industry Average ROCE: 48.42%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 10.49% (Industry Average ROE: 7.44%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 9.74
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.53
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 43.7 (Industry average Stock P/E: 261.45)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.02
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Syngene International Ltd. is a Public Limited Listed company incorporated on 18/11/1993 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L85110KA1993PLC014937 and registration number is 014937. Currently Company is involved in the business activities of Scientific research and development. Company's Total Operating Revenue is Rs. 3373.30 Cr. and Equity Capital is Rs. 402.50 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBiocon SEZ, Biocon Park, Bengaluru Karnataka 560099Contact not found
Management
NamePosition Held
Ms. Kiran Mazumdar ShawNon Executive Chairman
Mr. Peter BainsManaging Director & CEO
Prof. Catherine RosenbergNon Executive Director
Ms. Vinita BaliLead Independent Director
Mr. Nilanjan RoyIndependent Director
Dr. Kush ParmarIndependent Director
Ms. Sharmila Abhay KarveIndependent Director
Dr. Vijay KuchrooIndependent Director
Mr. Manja BoermanIndependent Director

FAQ

What is the intrinsic value of Syngene International Ltd?

Syngene International Ltd's intrinsic value (as of 20 February 2026) is ₹448.77 which is 1.07% higher the current market price of ₹444.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹17,880 Cr. market cap, FY2025-2026 high/low of ₹761/426, reserves of ₹4,332 Cr, and liabilities of ₹6,542 Cr.

What is the Market Cap of Syngene International Ltd?

The Market Cap of Syngene International Ltd is 17,880 Cr..

What is the current Stock Price of Syngene International Ltd as on 20 February 2026?

The current stock price of Syngene International Ltd as on 20 February 2026 is ₹444.

What is the High / Low of Syngene International Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Syngene International Ltd stocks is ₹761/426.

What is the Stock P/E of Syngene International Ltd?

The Stock P/E of Syngene International Ltd is 43.7.

What is the Book Value of Syngene International Ltd?

The Book Value of Syngene International Ltd is 118.

What is the Dividend Yield of Syngene International Ltd?

The Dividend Yield of Syngene International Ltd is 0.28 %.

What is the ROCE of Syngene International Ltd?

The ROCE of Syngene International Ltd is 13.5 %.

What is the ROE of Syngene International Ltd?

The ROE of Syngene International Ltd is 10.5 %.

What is the Face Value of Syngene International Ltd?

The Face Value of Syngene International Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Syngene International Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports